Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization
Jiajia Chen(Mayo Clinic), Jann N. Sarkaria(Mayo Clinic in Arizona), Katrina K. Bakken(Mayo Clinic in Arizona), Brendan A.C. Harley(Center for Genomic Science), Daniel J. Laverty(Massachusetts Department of Public Health), Rohit Bhargava(University of Illinois Urbana-Champaign), Rachael A. Vaubel(Mayo Clinic), William F. Elmquist(University of Minnesota), Danielle M. Burgenske(Mayo Clinic in Arizona), Jeanette E. Eckel‐Passow(Mayo Clinic in Florida), Surabhi Talele(University of Minnesota), Shiv K. Gupta(Mayo Clinic), Brett L. Carlson(University of California, San Francisco), Paul A. Decker(University of California, San Francisco), Zachary D. Nagel(Harvard University), Ashwin Bale(University of Illinois Urbana-Champaign), Petra Hamerlik(University of Manchester), Zhenkun Lou(Mayo Clinic in Arizona), Kendra A. Porath(Mayo Clinic)
Cited by 37
Related Papers
Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth
|The Journal of Experimental Medicine|2012|402
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
|Neuro-Oncology|2008|387
Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors
|Nature Genetics|2017|381
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
|Journal of Clinical Oncology|2008|275
A c-Myc–SIRT1 feedback loop regulates cell growth and transformation
|The Journal of Cell Biology|2009|233